IDEAYA is a synthetic lethality-focused precision medicine oncology company. We are passionately pursuing the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA has a world-class team of leading scientists and advisors with extensive knowledge and expertise in cancer biology, small molecule drug discovery, translational biology and clinical development. Our Scientific Advisory Board (SAB) consists of academic and industry thought leaders including members of the National Academy of Sciences and the National Academy of Medicine.

O ur team has built a robust pipeline of potential first-in-class and/or best-in-class precision medicine therapeutics. We have an ongoing target identification, validation and drug discovery research focus in synthetic lethality – an emerging class of precision medicine targets. Our most advanced pipeline programs include IDE397, a clinical stage MAT2A inhibitor targeting patients with tumors having MTAP gene deletion, which represents approximately 15% of solid tumors, as well as IDE196, a clinical stage PKC inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Since inception, IDEAYA’s research focus has been to exploit the concept of synthetic lethality, an approach for indirectly targeting oncogenic pathways. Certain genetic alterations in cancer cells enable tumor proliferation, but also create vulnerabilities – which we target with our therapeutics. In cancer cells with such genetic alterations, pharmacological inhibition of the target can cause cell death. In normal cells, without such genetic alternations, the target inhibition can be non-lethal – creating a therapeutic window. Patients for our therapeutics are selected using molecular diagnostics to identify the genetic alternation or a related biomarker.

We have established a strategic partnership with GlaxoSmithKline (GSK) on our Pol Theta and Werner Helicase synthetic lethality programs, and are collaborating with Pfizer pursuant to a clinical trial collaboration and supply agreement on our PKC program.

IDEAYA is headquartered in South San Francisco, California.

Management Team

Yujiro S. Hata

President and Chief Executive Officer

Michael White, Ph.D.

Chief Scientific Officer

Paul A. Stone, J.D.

Senior Vice President and Chief Financial Officer

Paul A. Barsanti, Ph.D.

Senior Vice President, Head of Drug Discovery

Mark Lackner, Ph.D.

Senior Vice President, Head of Biology and Translational Sciences

Jason S. Throne, J.D.

Senior Vice President, General Counsel

Mick O’Quigley

Senior Vice President, Development Operations

Andres Ruiz Briseno, C.P.A.

Vice President, Head of Business Operations and Investor Relations

Matthew Maurer, M.D.

Vice President, Head of Medical Affairs and Clinical Oncology

Scientific Advisory Board

Frank McCormick, Ph.D.

SAB Chair | Professor, University of California at San Francisco

Brian Daniels, M.D.

Director | Former SVP, Global Development and Medical Affairs, Bristol-Myers Squibb

Jeffrey Hager, Ph.D.

Former IDEAYA Chief Technology Officer

Trey Ideker, Ph.D.

Professor, University California at San Diego

William R. Sellers, M.D.

Core Institute Member, Broad Institute, Dana-Farber Cancer Institute, and Harvard Medical School

Elizabeth Swisher, M.D.

Professor, University of Washington

Board of Directors

Timothy Shannon, M.D.

Chairman of the Board | General Partner, Canaan Partners

Garret Hampton, Ph.D.

Director | President, Clinical Sequencing and Oncology, ThermoFisher Scientific

Yujiro S. Hata

Director | Chief Executive Officer, IDEAYA Biosciences

Susan L. Kelley, M.D.

Director | Former Chief Medical Officer of MMRC

Catherine Mackey, Ph.D.

Director | Former Senior Vice President of Pfizer Worldwide Research and Development

Scott Morrison

Director | Partner, Ernst & Young (retired)

Terry Rosen, Ph.D.

Director | Chief Executive Officer, Arcus Biosciences

Jeffrey Stein, Ph.D.

Director | President and Chief Executive Officer, Cidara Therapeutics

Wendy Yarno

Director | Former Executive Vice President and Chief Marketing Officer, Merck & Co.



Pol Theta, Werner Helicase

Pfizer Inc.

IDE196 (PKC)

University of California
San Diego

Synthetic Lethality Target Identification

Broad Institute

Biomarker and Translational Research

University of California
San Francisco

Biomarker and Translational Research